Alumis Alternatives & Competitors
12 companies similar to Alumis — Transforming the lives of patients living with immune-mediated diseases using a...
Companies similar to Alumis
3T Biosciences
3T is an immunotherapy company developing next-generation, transformative therapies for br...
Sudo Biosciences
Developing precision TYK2 therapeutics.
ACELYRIN, INC.
We are a late-stage clinical biopharma company focused on providing life-changing new trea...
HI-Bio: A Biogen Company
HI-Bio is a clinical-stage biotech company delivering targeted therapies for patients with...
Rival Readout
Competing with Alumis? We do this properly.
10 rivals, 90 days of dated moves, ranked by what matters and sourced, in 7 business days.
Entelexo Biotherapeutics
Entelexo has created a novel platform technology for engineering exosomes as a new approac...
Dianthus Therapeutics, Inc.
Building a leading biotech company focused in severe autoimmune diseases.
Expansion Therapeutics
Bringing transformative therapies to patients with severe RNA-mediated diseases.
ROME Therapeutics
Harnessing the power of the repeatome to develop a new class of therapies for cancer and a...
Adicet Bio, Inc
A biotechnology company discovering and developing first-in-class allogeneic gamma delta C...
Kite Pharma
At Kite, a Gilead Company, our singular focus is cell therapy to treat and cure cancer.
Tridek-One
We develop first-in-class CD31 checkpoint agonists for the treatment of auto-immune diseas...
About Alumis
Alumis, founded in 2021 and headquartered in the United States, is making strides in the biotechnology, health care, and life sciences industries. The company is committed to transforming the lives of patients with immune-mediated diseases through a precise, targeted approach. By focusing on optimizing patient outcomes...
Development of targeted therapies, Clinical trial management, Proprietary data analytics for precision medicine, Patient resources and expanded access policy
Patients with immune-mediated diseases, Healthcare providers, Medical researchers, Investors in biotech and pharmaceutical sectors
Immune-mediated Diseases, Precision Medicine, Targeted Therapies, Drug Development, Autoimmune Diseases, Immunology, Pharmaceuticals, Integrated Therapy Development, Immunosuppression Alternatives, Patient-centric Solutions, Disease-specific Drug Targeting, Therapeutic Innovation, Healthcare Analytics
B2B, D2C, B2D
Product Sales, Licensing, Performance Based
Frequently Asked Questions
From the desk
Mapping a market? Start with a Rival Readout.
In 7 business days we read 10 rivals around Alumis: 90 days of dated moves, ranked by what matters to you, each with its source. Fully credited if you continue.
Compiled from the BounceWatch company index. We last looked at Alumis on 9 Jun 2026. The 12 companies listed here were last checked between 12 Sep 2024 and 10 Jun 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.